Strategic Growth Target international expansion and board-level partnerships leveraging the recent Non-Executive Director appointments to open discussions with potential distributors, contract manufacturers, and specialty pharma networks in the UK and Europe.

Niche Portfolio Position Essentia as a source for mature, well-established products in niche therapeutic areas with sustainable access needs, offering opportunities to secure supply agreements, orphan/non-acute indications, and high-margin legacy product lines.

Asset Acquisition Synergy Leverage the history of acquisitions from major players (e.g., Novartis assets) to propose asset-backed collaborations, licensing deals, or co-development arrangements that reduce time-to-market and expand the product catalog.

Financial Triggers Even with sub‑$1M revenue, highlight scalable opportunities in global markets, value-based pricing, and cost-efficient manufacturing partnerships that can attract investors or strategic buyers seeking low-volume, high-need products.

Leadership Outreach Engage Emma Johnson and other senior executives on CFO/CEO level conversations to discuss financing rounds, strategic alliances, and long-term supply commitments to support growth and market access initiatives.